48. Рапопорт С.И. Гастриты: пособие для врачей / С.И. Рапопорт. - М.: ИД «МЕДПРАКТИКА-М», 2010. - 20 с.
49. Распространенность инфекции H. pylori среди населения Москвы / С.В. Герман, И.Е. Зыкова, А.В. Модестова, Н.В. Ермаков // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2010. - Т. 20, № 2. - С. 25-30.
50. Решетников О.В. Распространенность атрофического гастрита в разных популяциях Сибири по данным серологического исследования / О.В. Решетников, С.А. Курилович, С.А. Кротов // Клин. мед. - 2008. - № 7. - С. 35-38.
51. Рысс Е.С. Введение в гастроэнтерологию / Е.С. Рысс. - СПб: СпецЛит, 2005. - 54 с.
52. Состав кишечной микрофлоры при эрадикационной терапии у больных язвенной болезнью / Л.М. Мосина, Л.В. Матвеева, Е.А. Митина, А.Е. Гераськин // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2011. - Т. 21, № 5. - С. 54.
53. Сотников В.Н. Эндоскопическая диагностика и эндоскопические методы лечения кровотечений из верхних отделов пищеварительного тракта: учебное пособие / В.Н. Сотников, Т.К. Дубинская, А.А. Разживина. - М.: РМАПО, 2000. - 48 с.
54. Социально значимые заболевания населения России в 2010 году (статистические данные). - М.: Минздравсоцразвития РФ, 2011. -С. 65-66.
55. Сравнительное изучение эффективности различных методов диагностики хеликобактерной инфекции / Л.Б. Лазебник [и др.] // Экспериментальная и клиническая гастроэнтерология. 2004. - № 1. - С. 15-17.
56. Старостин Б.Д. Эрадикация Helicobacter pylori у пациентов с хроническим хеликобактерным гастритом / Б.Д. Старостин, Г.А. Старостина // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2011. - Т. 21, № 5. - С. 36.
57. Субботин А.М. Опыт внедрения скрининга раннего рака и предраковых изменений слизистой желудка в условиях практической медицины / А.М. Субботин, А.В. Разумовский // Сибирский журнал гастроэнтерологии и гепатологии. - 2005. - № 19. - С. 163-169.
58. Субпопуляционный состав лимфоцитов слизистой оболочки желудка у пациентов с хроническим гастритом / Н.В. Бычкова Н.В., И.А. Михайлова, Н.И. Давыдова [и др.] // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2011. - Т. 21, № 5. - С. 22.
59. Трофимов Д.Н. Опухолевая патология желудка в общей врачебной практике: учебное пособие для системы послевузовского профессионального образования врачей / Д.Н. Трофимов. - Ниж.Новгород, 2007. - С. 87-88.
60. Хомерики С.Г. Новые подходы к морфологической классификации хронического гастрита / С.Г. Хомерики // Consilium medicum. Гастроэнтерология. - 2008. - № 1. - С. 11-15.
61. Циммерман Я.С. Актуальные проблемы клинической гастроэнтерологии: клинические очерки / Я.С. Циммерман. - Пермь, 2008. - 167 с.
62. Цуканов В.В. Заболеваемость, факторы риска и возмжности профилактики рака желудка у населения России / В.В. Цуканов, О.С. Амельчугова // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2011. - Т. 21, № 5. - С. 38.
63. Чиссов В.И. Онкология. Клинические рекомендации / В.И. Чиссов, С.Л. Дарьялова. - М.: «ГЭОТАР-Медиа», 2006. - 317с.
64. Шапошников A.B. Предраковые заболевания желудка / A.B. Шапошников // Клиническая медицина. - 2007. - № 2. - С.4-8.
65. Шептулин А.А. Хронический гастрит и функциональная диспепсия: есть ли выход из тупика? / А.А. Шептулин // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2010. - Т. 20, № 2. - С. 84-87.
66. A Coordinated Cytotoxic Effect of IFN-г and Cross-Reactive Antibodies in the Pathogenesis of Helicobacter pylori Gastritis / T. Itoh [et al.] // Helicobacter. - 2003. - Vol. 8, N 4. - P. 268-278.
67. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains / N. Salama [et al.] // Proc Natl Acad Sci USA. - 2000. - Vol.97. - P. 14668-14673.
68. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis / A.C. Ford // World J Gastroenterol. - 2008. - N 48. - Р. 7361-7371.
69. Alcohol and tobacco use in relation to gastric cancer: a prospective study of men in Shanghai, China / K.A. Moy [et al.] // Cancer Epidemiol. Biomarkers Prev. - 2010. - Vol. 19. - P. 2287-2297.
70. Alteration of histological gastritis after cure of Helicobacter pylori / M. Hojo [et al.] // Aliment. Pharmacol. Ther. - 2002. - Vol. 16. - P. 1923-1932.
71. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan / N. Horiki [et al.] // Helicobacter. - 2009. - N 14. - Р. 86-91.
72. Aspirin use and the risk of gastric cancer: a meta-analysis / P. Yang [et al.] // Dig. Dis. Sci. - 2010. - Vol. 55. - P. 1533-1539.
73. Association of peptic ulcer with increased expression of Lewis antigens but not cagA, iceA, and vacA in Helicobacter pylori isolates in an Asian population / P.Y. Zheng [et al.] // Gut. - 2000. - Vol.47. - P. 18-22.
74. Axon A. H. pylori eradication for prevention gastric cancer / A. Axon // Management of H. pylori infection: The Maastricht 4 Consensus. Symposium 19.UEGW. - Stockholm, 2011. - Oral presentation.
75. Bae S. Effect of eradication of Helicobacter pylori on recurrence after endoscopic mucosal resection of gastric adenoma and early gastric cancer / S. Bae, H. Jung, K. Choi // Helicobacter. - 2011. - Vol. 16 (suppl. 1). - P. 92 (Abstract).
76. Biopsy from the base of gastric ulcer may find gastric cancer earlier / S.X. Lv [et al.] // Med Hypotheses. - 2011. - N 76(2). - P. 249-253.
77. Bisschops R. Confocal laser endomicroscopy: finally ready to change clinical practice? / R. Bisschops // Gastrointest Endosc. - 2011.- Oct;74(4). - P. 781-787.
78. Broccoli consumption and chronic atrophic gastritis among Japanese males: an epidemiological investigation / K. Sato [et al.] // Acta Med. Okayama. - 2004. - Vol. 58, N 3. - P. 127-133.
79. CagA protein seropositivity in a random sample of adult population and gastric cancer patients in Estonia / T. Vorobjova [et al.] // Eur J Gastroenterol Hepatol. - 2001. - Vol.9. - P. 41-47.
80. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection / R. Hunt [et al.] // Can. J. Gastroenterol. - 2004. - Vol. 18. - P. 547-554.
81. Ceung T.K. Treatment of Helicobacter pylori and prevention of gastric cancer / T.K. Ceung, B. Cy Wong // J. Dig. Dis. - 2008. - Vol. 9. - P. 8-13.
82. Chapman M.A. The role of the colonic flora in maintaining a healthy large bowel mucosa / M.A. Chapman // Ann R Coll Surg Engl. - 2001. - Vol.83. - P. 75-80.
83. Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia / H.H. Xia [et al.] // Aliment Pharmacol Ther. - 2003. - Vol.17. - P. 935-943.
84. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from 9-year prospective follow-up study in Japan / T. Kamada [et al.] // Aliment. Pharmacol. Ther. - 2005. - Vol. 21. - P. 1121-1126.
85. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer / H. Alakus [et al.] // World J Surg. - 2010. - N 34(12). - P. 2853-2859.
86. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review / M. Ito [et al.] // J. Gastroenterol. - 2009. - Vol. 44. - P. 365-371.
87. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori / L.J. Van Doorn [et al.] // Gastroenterology. - 2001. - Vol.117. - P. 58-67.
88. Clonal analysis of gastric carcinoma and precancerous lesions and its relation to Ki-67 protein expression / L. Zheng, S.Y. Wang [et al.] // Neoplasma. - 2009. - N 56(l). - Р. 48-57.
89. Clustering of Clinical Strains of Helicobacter pylori Analyzed by Two-Dimensional Gel Electrophoresis / H. Enroth // Clin. diagn. lab. immunol. - 2000. - Vol. 7, N 2. - P. 301-306.
90. Colagar A.H. Fourier transform infrared microspectroscopy as a diagnostic tool for distinguishing between normal and malignant human gastric tissue / A.H. Colagar, M.J. Chaichi, T. Khadjvand // J Biosci. - 2011. - N 36(4). - P. 669-677.
91. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection / M.P. Dore [et al.] // Am J Gastroenterol. - 2002. - N 97. - Р. 857-869.
92. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus / R.J. Loffeld [et al.] // Digestion. - 2000. - Vol.62. - P. 95-99.
93. Correa P. Pathology of gastric intestinal metaplasia: clinical implications / P. Correa, M.B. Piazuelo, K.T. Wilson // Am J Gastroenterol. - 2010. - N105(3). - P. 493-499.
94. Could the 10-days sequential therapy be considered a first choice treatment for the eradication of Helicobacter pyloriinfection? / R. Focareta [et al.] // Dig. Liver Dis. - 2003. - Vol. 35 (suppl. 4). - P. 33.
95. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial / E.J. Kuipers [et al.] // Gut. - 2004. - N1. - Р. 12-23.
96. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report / P. Malfertheiner [et al.] // Gut. - 2007. - Vol. 56. - P. 772-781.
97. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease / R. Befrits [et al.] // Helicobacter. - 2000. - Vol.5. - P. 202-205.
98. Development of type I gastric carcinoid in patients with chronic atrophic gastritis / L. Vannella [et al.] // Aliment Pharmacol Ther. - 2011. - N 33(12). - Р. 1361-1367.
99. Di Mario F. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium / F. Di Mario, L.G. Cavallaro, A.M. Moussa // Dig. Dis. Sci. - 2006. - Vol. 51, N 10. - P. 1791-1795.
100. Dirschmid K. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis / K. Dirschmid, M. Stolte // Am J Surg Pathol. - 2011. - N 35(8). -Р. 1245.
101. Discrepancy Between Polymerase Chain Reaction Assay and Western Blot Analysis in the Assessment of CagA Status in Dyspeptic Patients / O.A. Paoluzi [et al.] // Helicobacter. - 2001. - Vol.6, N 2. - P. 130-135.
102. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial / K. Fukase // Lancet. - 2008. - Vol. 372. - P. 392-397.
103. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma / K. Saito [et al.] // Gastrointest Endosc. - 2000. - Vol.52. - P. 27-32.
104. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with nonulcer dyspepsia / V. De Francesco [et al.] // Aliment. Pharmacol. Ther. - 2004.- Vol. 19. - P. 993-998.
105. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice / J. Delgado [et al.] // Gastroenterology. - 2007. - Vol. 132. - P. 112.
106. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran / F. Islami [et al.] // Br J Cancer. - 2004. - N 90. - Р. 1402-1406.
107. Epidemiological trends of pre-malignant gastric lesions; a long-term nationwide study in the Netherlands / A.C. De Vries [et al.] // Gut. - 2007. - 56. - Р. 1665-70.
108. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century / M.P. Coleman [et al.] // Ann. Oncol. - 2003. - Vol. 5 (suppl. 14). - P. 128-149.
109. Evaluation of Gastric Atrophy. Comparison between Sidney and OLGA Systems / P. Ramнrez-Mendoza, J. Gonzбlez-Angulo, U. Angeles-Garay, G.A. Segovia-Cueva //Rev Med Inst Mex Seguro Soc. - 2008. - 46 (2). - Р. 135-9.
110. Ferlay J. GLOBOCAN 2002: cancer incidence, mortality and prevalence world-wide / J. Ferlay, F. Bray, P. Pisani. - Lion: IARC Press, 2004.
111. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets / S.B. Garcia [et al.] // J Pathol. - 1999. - N 187. - Р. 61- 81.
112. Functional gastroduodenal disorders / J. Tack [et al.] // Gastroenterology. - 2006. - Vol. 130, N 5. - P. 1466-1479.
113. Fundal atrophic gastritis as a risk factor for gastric cancer / M. Tatsuta [et al.] // Int J Cancer. - 2003. - N 55. - Р. 70-3.
114. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis / J. Wang [et al.] // Digestion. - 2011. - Vol. 83. - P. 253-260.
115. Gastric cancer: basic aspects / C. Resende [et al.] // Helicobacter. - 2011. - Vol. 16 (suppl. 1). - P. 38-44.
116. Gastric cancer: clinical aspects, epidemiology and molecular background / L. Bornschein, T. Rokkas, M. Selgrad, P. Malfertheiner // Helicobacter. - 2011. - Vol. 16 (suppl. 1). - P. 45-52.
117. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands / A.C. De Vries [et al.] // Gastroenterology. - 2008. - Vol. 134, N 4. - P. 945-952.
118. Gastric foveolar metaplasia and gastric heterotopia in the duodenum: no evidence of an etiologic role for Helicobacter pylori / R.M. Genta [et al.] // Hum Pathol. - 2010. - N 41(l 1). - P. 1593-1600.
119. Gastritis staging in clinical practice: the OLGA staging system / M. Rugge, A. Meggio, G. Pennelli [et al.] // Gut. - 2007. - N 56. - Р. 631-639.
120. Gene structure of the Helicobucter pylori cytotoxin and evidence of its key role in gastricdisease / J.L. Telford [et al.] // JExpMed. - 2003. - Vol.169. - P. 1653-1659.
121. Gillen D. Effect of H. pylori eradication on precancerous lesions / D. Gillen // Gut. - 2005. - 54. - P.1511.
122. Global cancer statistics, 2002 / D.M. Parkin [et al.] // CA Cancer J. Clin. - 2005. - Vol. 55. - P. 74-108.
123. Gonzales C.A. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis / C.A. Gonzales, L. Lopez-Carillo // Scand. J. Gastroenterol. - 2010. - Vol. 45. - P. 6-14.
124. Graham D.Y. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod / D.Y. Graham, M. Asaka // J. Gastroenterol. - 2010. - Vol. 45, N 1. - P. 1-8.
125. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole / H.B. Yang [et al.] // Am J Gastroenterol. - 2009. - N 7. - Р. 1642-9.
126. Helicobacter and Cancer Collaborative Group. Gastric cancer and H. pylori: a combined analysis of 12 case control studies nested within prospective cohorts // Gut. - 2001. - Vol. 49. - P. 347-353.
127. Helicobacter pylori and the development of atrophic gastritis / S. Takahashi [et al.] // Nippon Rinsho. - 2003. - Vol.51(12).- P. 3231-3235.
128. Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis / R.M. Jr. Peek [et al.] // J. Natl. Cancer Inst. - 2001. - Vol.79. - P. 763-768.
129. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the art critique / P. Malfertheiner [et al.] // Am. J. Gastroenterol. - 2005. - Vol. 100. - P. 2100-2115.
130. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial / B.C. Wong [et al.] // JAMA. - 2004. - Vol. 291, N 2. - P. 187-194.
131. Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients: a metaanalysis / T. Rokkas [et al.] // Eur. J. Gastroenterol. Hepatol. - 2011. - Vol. 83. - P. 253-260.
132. Helicobacter pylori infection and the development of gastric cancer / N. Uemura [et al.] // N Engl J Med. - 2001. - N 345. - Р. 784-789.
133. Helicobacter pylori membrane protein 1. A new carcinogenic factor of Helicobacter pylori / M. Suganuma [et al.] // Cancer Res. - 2001. - Vol. 61. - P. 6356-6359.
134. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses / D.A. Israel [et al.] // J. Clin. Invest. - 2001. - Vol.107. - P. 611-620.
135. High eradication rates of Helicobacter pylori with a new sequential treatment / A. Zullo [et al.] // Aliment. Pharmacol. Ther. - 2003. - Vol. 17. - P. 719-726.
136. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication / Q. Sun [et al.] // Helicobacter. - 2010. - N 15(3). - Р. 233-9.
137. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain / S. Agudo [et al.] //J Clin Microbiol. - 2010. - N 48(10). - Р. 3703-8.
138. Histologic and immunohistochemical analyses of a-fetoprotein--producing cancer of the stomach / T. Kinjo [et al.] // Am J Surg Pathol. - 2012. - N 36 (l). - P. 56-69.
139. Houghton J. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers / J. Houghton, T. C. Wang // Gastroenterology. - 2005. - № 6. - V.128. - P. 1567-1573.
140. Hunt R.H. Risks of untreated H. pylori infection / R. Н. Hunt // AGA Institute Postgraduate Course. - 2006. - P. 333-348.
141. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial / R. Francavilla [et al.] // Gastroenterology. - 2005. - Vol. 129. - P. 1414-1419.
142. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori / E.M. El Omar [et al.] // Gastroenterology. - 2000. - Vol. 118. - P. 22-30.
143. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms / E.M. Omar [et al.] // Gastroenterology. - 2003.- Vol.124.- P. 1193-1201.
144. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype / M. Cassaro J [et al.] // Clin Pathol. - 2007. - N 60 (6). - Р. 615-21.
145. Interferon-gamma induced cell death in a cultured human salivary gland cell line / A.J. Wu [et al.] // J Cell Physiol. - 2002. - Vol.163. - P. 297-307.
146. Interferon-gamma induces interleukin-1 converting enzyme expression in pancreatic islets by an interferon regulatory factor-1-dependent mechanism / A.E. Karlsen [et al.] // J Clin Endocrinol Metab. - 2000. - Vol.85. - P. 830-836.
147. Interleukin-1 polymorphisms associated with increased risk of gastric cancer / E.M. El Omar [et al.] // Nature. - 2000. - Vol. 404. - P. 398-402.
148. Investigation of gastric cancer occured in successful H. pylori eradication and persistent H. pylori infected patients / M. Kato [et al.] // Gastroenterology - 2005. - Vol. 128 (suppl. 2). - Abstract M1346.
149. Israel D.A. Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation / D.A. Israel, R.M. Peek // Aliment Pharmacol Ther. - 2001. - Vol.15. - P.1271-1290.
150. Kashiwagi H. Ulcers and gastritis / H. Kashiwagi // J. Tradit Chin Med. - 2004. - Vol.24 (4). - P. 252-255.
151. Kato S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years / S. Kato, S. Fujimura // Pediatr Int. - 2010. - N 52(2). - Р.187-92.
152. Koh T.C. Tumors of the stomach / T.C. Koh, T.C. Wang // Sleisenger and Fordtran's gastrointestinal and liver disease / Ed. Feldman M. [et al.]. - 7th ed. - Philadelphia- London-Toronto-Montreal-Sydney-Tokyo, 2002. - P. 829-855.
153. Kuniyasu H. Helicobacter pylori infection and carcinogenesis of the stomach / H. Kuniyasu, W. Yasui, H. Yokozaki // Langenbecks Arch Surg. - 2000. - Vol. 385, N 2. - P.69-77.
154. Leja M. Gastric cancer: epidemiology, diversity and pathogenesis / M. Leja / GI Oncology and Innovative Aspects in Gastroenterology / Ed. Arnold R. [et al.]. - Paris, 2005. - P. 63-68.
155. Longterm results of gastric cancer screening using the the serum pepsinogen test method among an asymptomatic middle-aged Japanese population / K. Miki [et al.] // Dig. Endosc. - 2009. - Vol. 21, N 2. - P. 78-81.